Mar­ket­ing pay­ments to can­cer doc­tors lead to more pre­scrip­tions but not bet­ter out­comes, NBER pa­per finds

Can­cer drug­mak­ers’ mar­ket­ing pay­ments to physi­cians do work, but they don’t im­prove pa­tient mor­tal­i­ty, ac­cord­ing to a new Na­tion­al Bu­reau of Eco­nom­ic Re­search work­ing pa­per.

Re­searchers tracked an in­crease in Medicare pre­scrip­tions in the 12 months af­ter physi­cians re­ceived mar­ket­ing pay­ments, but al­so found “no changes” in sur­vival among those same physi­cians’ pa­tients.

The re­searchers from Cor­nell Uni­ver­si­ty and Uni­ver­si­ty of Wash­ing­ton used pay­ment da­ta from the Open Pay­ments data­base, which in­clude meals, speak­er fees and con­sult­ing fees from phar­ma com­pa­nies to physi­cians. 67% of the physi­cians in the sam­ple re­ceived at least one can­cer drug mar­ket­ing pay­ment dur­ing the 2014-2018 study pe­ri­od. The re­search is cur­rent­ly in re­view at NBER.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER